CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors would like to thank the patients and their families, as well as clinical researchers and their teams who have participated in this study. The authors thank Tim Burn, PhD, for his input on this manuscript. Medical writing assistance was provided by Ori Bowen, PhD, of Syneos Health.

Authors contributions

All authors contributed to data acquisition, manuscript development, and approval. All authors interpreted the results and agree on accountability for all study aspects, including accuracy, integrity, and protocol adherence. All authors contributed to study design or conduct, data analyses, or manuscript writing.

Disclosure statement

J. Duell’s institution has received patient fees from MorphoSys. A. Obr reports consultancy fees from Janssen and honoraria from Roche. M. Augustin reports consultancy fees from Bristol-Myers Squibb, MSD, Pfizer, PharmaMar, IPSEN, AstraZeneca; research funding (institution) from Bristol-Myers Squibb, MSD, Morphosys, AstraZeneca, Pfizer, PharmaMar; travel expenses from Lilly, Novartis, Bristol-Myers Squibb, PharmaMar and IPSEN. J. Endell, S. Geiger, and S. Ambarkhane are employees of MorphoSys AG. H. Liu and I.M. Silverman are employees and stockholders of Incyte Corporation.

About tafasitamab

Tafasitamab is a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc.

Tafasitamab incorporates an XmAb^® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).

In January 2020, MorphoSys and Incyte entered into a collaboration and licensing agreement to further develop and commercialize tafasitamab globally. Following accelerated approval by the U.S. Food and Drug Administration in July 2020, tafasitamab is being co-commercialized by MorphoSys and Incyte in the United States. Incyte has exclusive commercialization rights outside the United States.

XmAb^® is a trademark of Xencor, Inc.

Additional information

Funding

This work is funded by MorphoSys AG.